Security record · archived quarter
COLL
Collegium Pharmaceutical, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
1Tracked holders
-2Δ holders
7.16KShares held
$156,275Reported value
+0New positions
−2Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -2 | 7.16K | $156,275 | n/a | −2 |
| Q2 2026 | 98 | +3 | 27.25M | $986.22M | +8 | −5 |
| Q1 2026 | 98 | -1 | 28.14M | $930.88M | +7 | −9 |
| Q4 2025 | 100 | 0 | 26.92M | $1.25B | +1 | n/a |
| Q3 2025 | 19 | +2 | 14.79M | $517.39M | +2 | n/a |
| Q2 2025 | 14 | +1 | 12.36M | $365.37M | +1 | n/a |
| Q1 2025 | 10 | -1 | 5.48M | $163.49M | n/a | −1 |
| Q4 2024 | 11 | -1 | 5.00M | $143.28M | n/a | −1 |
| Q3 2024 | 11 | -1 | 3.77M | $145.78M | n/a | −1 |
| Q2 2024 | 12 | n/a | 3.67M | $118.10M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assetmark, Inc | 7.16K | +19.1% | $156,275 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assenagon Asset Management… | $22.37M | was 0.0% |
| Robeco Institutional Asset… | $424,300 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 264 holders, 37.57M shares, $1.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API